<DOC>
	<DOCNO>NCT01253434</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics single dose E2022 healthy Japanese male volunteer .</brief_summary>
	<brief_title>E2022 Patch Formulation Single Dose Phase I Study</brief_title>
	<detailed_description>This study open-label single site , randomize single dose study 80 healthy Japanese male volunteer . The study consist Period I Period III , total 3 period . In Period I , E2022 patch secure seal . In Period II , single dose E2022 5 mg tablet administer . In Period III , E2022 patch apply without seal . The feature 5 patch evaluate study .</detailed_description>
	<criteria>Inclusion Criteria 1 . Body Mass Index ( BMI ) Screening 18.5 kg/m2 less 25.0 kg/m2 : BMI ( kg/m2 ) = weight ( kg ) รท { height ( ) ร height ( ) } 2 . Subjects 20 55 year age time obtain write consent . 3 . Subjects willing comply condition describe study protocol . Exclusion Criteria 1 . Subjects consume caffeinecontaining food beverage within 72 hour study drug administration . 2 . Exposure supplement herbs ( include Chinese medicine ) , beverage ( e.g . alcohol grapefruitcontaining beverage ) know modulate CYP3A4 , CYP2C9 , CYP2C19 , CYP2D6 , within 2 week study drug administration . 3 . Subjects history cutaneous hypersensitivity external preparation , another transdermal formulation . 4 . Subjects excessive skin hair around region put patch . 5 . Subjects skin disorder , eczema , skin irritation , pigment disorder , injury scar region patch application , may impact skin finding .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Transdermal Administration</keyword>
</DOC>